The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...
The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...
A new study into the online conversations of healthcare professionals discussing prostate cancer has revealed a strong focus on emerging therapies, the latest clinical trials, AI-driven diagnostics ...
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Symbravo Outperforms Oral CGRP Inhibitors in Phase III Trial, With Faster, Sustained Migraine Relief
Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
The application was based on results from the three-arm Phase 3 CheckMate -8HW study.
HPV16+ Cancers Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, ...
Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.
Sinar Daily on MSN3d
Seven-year trial shows 48 per cent survival with dual immunotherapyPatients with advanced melanoma that had spread to the brain were previously expected to survive for only 16 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback